Agennix
Martinsried
About Agennix
Agennix AG is a publicly listed biopharmaceutical firm focused on developing innovative therapies to address significant unmet medical needs, aiming to enhance both the duration and quality of life for patients with serious illnesses. The Company's leading program is talactoferrin, an oral targeted therapy that has shown efficacy in randomized, double-blind, placebo-controlled Phase 2 trials for non-small cell lung cancer and severe sepsis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $139.6M
- Funding stage: IPO
- Last round: Series Unknown (Oct 2010)
- Ticker: fra:AGX
- Website: agennix.com
- Phone: +49 89 85 65 2600
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/agennix-912197 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.